tbuckley/cabot-search huggingface dataset:
Iodine-131 MIBG Imaging in Multiple Endocrine Neoplasia Type 2B
Authors: YUKA YAMAMOTO, YUKO ISOBE, YOSHIHIRO NISHIYAMA, HITOSHI TAKASHIMA, MOTOOMI OHKAWA, MINORU KIHARA, KENICHI MATSUSAKA, AKIRA MIYAUCHI, SHOJI KOBAYASHI, MASATADA TANABE
Journal: Clinical Nuclear Medicine (1998)

A 16-year-old boy had a swollen neck that was a result of multiple endocrine neoplasia Type 2B (MEN 2B). CT revealed bilateral thyroid tumors, swelling of right cervical lymph nodes, and slight enlargement of the right adrenal gland. I-131 metaiodobenzylguanidine (MIBG) scintigraphy demonstrated increased uptake in the right adrenal gland and the left thyroid tumor, but no abnormal uptake in the right thyroid tumor and the right cervical lymph nodes. Postoperative pathologic findings were consistent with the diagnosis of right adrenal medullary hyperplasia, which is a precursor of pheochromocytoma. In patients with MEN 2B, I-131 MIBG scintigraphy in conjunction with CT of the adrenal glands should be performed to determine the disease stage of the adrenal medullae. In the cervical region, the diagnosis was medullary thyroid carcinoma (MTC) in both thyroid tumors and metastases in the right cervical lymph nodes. The right MTC was more aggressive than the left MTC. It is interesting that not all sites of known MTC take up I-131 MIBG to the same degree.
Abstract 5224: Tracking the longitudinal physiological and vascular morphology changes in response to anti-angiogenesis treatment in breast tumors
Authors: Ning Cao, Minsong Cao, Bo Liu, Kathy D. Miller, Keith Stantz
Journal: Cancer Research (2010)

Abstract VEGF and its receptor (VEGFR2 or flk1/KDR) play critical roles in tumor angiogenesis, which is essential for tumor growth and metastasis. The objective of this study is to track and quantify the longitudinal intra-tumor heterogeneous response to anti-VEGFR2 treatment using a combination of imaging modalities: dynamic contrast-enhanced CT (DCE-CT) and photoacoustic computed tomography (PCT). DCE-CT is used to measure vascular physiology and PCT is used to monitor its morphological changes based on its hemoglobin status within the tumor. A cohort of athymic mice bearing MCF-7VEGF (MCF-7 cells transfected with VEGF gene) tumors were divided into three groups: a control group (received non-specific, rat immunoglobulin IgG1, i.v.), a low dose therapeutic group (30 mg/kg DC101, i.v.), and a high dose therapeutic group (150 mg/kg DC101, i.v.). Twenty-four hours prior to treatment, baseline DCE-CT and PCT scans were acquired. Successive scans were taken 2 days, 1 week, and 2 weeks post treatment to track both physiological and morphological changes. For the former, a two-compartmental kinetic model is fit to contrast enhanced curves on a voxel-by-voxel basis to determine tumor physiological parameters of perfusion (F), permeability-surface area (PS), fractional plasma volume (fp) and fractional interstitial space (fis). Maximum intensity profiles (MIPs) and hemoglobin profiles were extracted from PCT images. The preliminary results show a dose dependent response to DC101 treatments. Two days post treatment, low dose reduced F by 36% and fp by 22%; high dose reduced F by 72% and fp by 39%. Tumor perfusion remained reduced two weeks post treatment, while fp in treated mice rebounded to similar levels as the control group after one week and exceeded the control group by week two. This decoupling of fp and F over time indicates a step-wise progressive nature to the formation of a vascular network and its functionality associated with the VEGF/VEGFR2 pathway. Photoacoustic results confirm the link between the changes in vascular morphology and physiology, and provide an in vivo link between vascular structure and function in response to anti-angiogenic therapy. Future work will focus on measuring the oxygen saturation levels and hemoglobin concentration in tumors by analyzing the spectroscopic information afforded by PCT. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5224.
AB0608 Elevated Circulating Tumor-Associated Antigens in Systemic Sclerosis: Association with Lung Fibrosis
Authors: A. Vacca, V. Ibba, M. Cristo, G. Dessole, P. Garau, M. Piga, G. Porru, F. Figus, M. Dessì, A. Cauli, A. Mathieu
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Some tumor-associated antigens (TAAs), apart from cancer cells, are expressed on the surface of inflammatory cells. The production of some TAAs may also be increased in some autoimmune diseases including systemic sclerosis (SSc). <h3>Objectives</h3> To assess serum carcinoembryonic antigen (CEA), CA-15.3, CA 125, CA-19.9 levels in SSc patients, and to identify any possible associations with lung involvement parameters. <h3>Methods</h3> Eighty-two SSc patients (70 females and 12 males), mean age 64±13 years (range 34-91), disease duration 6±5 years (range 1-27), were consecutively studied. None of the patients ever had any malignancies. Serum TAAs determination were considered and all patients underwent to high-resolution scan (HRCT) and pulmonary function tests (PFTs). CEA, CA 19.9, CA 15.3 and CA125 were determined by electrochemiluminescence immunoassays; the normal upper limit determined by the manufacturer, were as follows: CEA &lt;2.5 ng/ml, CA19.9 &lt;33 U/ml, CA 15.3 &lt;46.5 U/ml, CA125 &lt;21 U/ml. <h3>Results</h3> CEA was elevated in 28 (32%) of SSc patients, CA 19.9 in 7 patients (9%), CA 15.3 in 28 patients (36%), CA 125 in 6 patients (8%). Lung fibrosis at HRCT significantly associated with CEA (p&lt;0.0003, r=0.4), CA15.3 (p&lt;0.001, r=0.4), and CA125 (p&lt;0.01, r=0.3) while no association was seen for CA 19.9. Forced vital capacity (FVC) significantly associated only with CA 15.3 (p=0.0001), and diffusion lung capacity for carbon monoxide (DLCO) only with CEA (p=0.04). There was an inverse correlation between CA 15.3, FVC and DLCO (r= -0.52 and r= -0.44, respectively). <h3>Conclusions</h3> The production of some TAAs may be elevated in SSc patients; CEA, CA15.3, and CA125 may have a negative prognostic role, being associated with lung fibrosis as documented by HRCT and PFTs. Further studies on higher proportion of patients could be addressed for identifying a surrogate biomarker, among TAAs, for lung involvement in SSc, to assess extent of the disease and possibly with prognostic significance. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5074
Antibiotic Synergism and Antagonism
Authors: E. Jawetz, J. B. Gunnison, R. S. Speck
Journal: New England Journal of Medicine (1951)

THE chemotherapeutic armamentarium of the physician has recently grown considerably. The question is no longer merely whether to give penicillin; the choice must now be made among half a dozen or more efficient antimicrobial agents that can be used to advantage in many infectious processes. With the availability of several good drugs the idea naturally arises of using them in combinations rather than singly. It appears reasonable to suppose that if one drug is useful two employed simultaneously should be better and three should ensure the patient's recovery. Considerations of this kind have led to a great increase in the . . .
Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus
Authors: Juhani Partanen, Leo Niskanen, Juha Lehtinen, Esa Mervaala, Onni Siitonen, Matti Uusitupa
Journal: New England Journal of Medicine (1995)

There is little information on the incidence and natural history of neuropathy in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Hepatocellular Carcinoma Monitored by F-18 Fluorodeoxyglucose Positron Emission Tomography After Laparoscopic Microwave Coagulation Therapy
Authors: HIROYASU MORIKAWA, SUSUMU SHIOMI, NOBUMITSU SASAKI, HISATO JOMURA, HIROKI SAKAGUCHI, SHUHEI NISHIGUCHI, SUICHI SEKI, TETSUO KUROKI, SHOJI KUBO, JOJI KAWABE, HIRONOBU OCHI
Journal: Clinical Nuclear Medicine (1999)

A 46-year-old woman was hospitalized for treatment of hepatocellular carcinoma. On admission, positron emission tomography with F-18 fluorodeoxyglucose (FDG PET) showed a hot spot that coincided with the tumor; its standardized uptake value (SUV) was 5.47. Two weeks and 6 months after laparoscopic microwave coagulation therapy, FDG PET showed a reduction in radioactive uptake to less than the background level, and the SUVs were 0.46 and 0.50, respectively. FDG PET performed 18 months after treatment showed a hot spot on the abdominal side of the site treated previously, and the SUV was 3.19. However, CT and MRI showed no evidence of recurrence. Our findings indicate that FDG PET is useful for evaluating the response to treatment and disease recurrence in patients with hepatocellular carcinoma.
Abstract 1651: Regulation of omental seeding of ovarian cancer cells by SPARC.
Authors: Dylan P. Matthews, Neveen A. Said
Journal: Cancer Research (2013)

Abstract Epithelial Ovarian cancer is the leading cause of death from malignant gynecologic tumors, as most patients have extensive late metastatic disease at the time of diagnosis. Ovarian cancer (OvCa) cells have specific predilection to metastasize to omentum, a condition known as “peritoneal ovarian carcinomatosis, POC” but rarely leave the peritoneal cavity. Despite aggressive surgical debulking and cytoreduction, recurrence of omental implants is high with poor patient survival. We have recently reported that the tumor suppressor role of matricellular glycoprotein SPARC (secreted protein acidic and rich in cysteine) in POC through differential effects on OvCa cells and their interactions with components of the peritoneal microenvironment. Given that SPARC is the first known matricellular protein involved in adipose tissues homeostasis, we sought to elucidate the potential roles of SPARC on the omental adipocyte-OvCa cells cross-talk and its impact on POC, in vivo and in vitro. Using primary omental SP−/− and SP+/+ omental stromal cells, we found that adipocyte-SPARC delayed the adipogenic differentiation of omental stromal cells. SP−/- omental adipocytes expressed significantly higher levels of adipogeneic markers and accumulated significantly less oil droplets than SP+/+. Primary SP−/− adipocytes promoted homing of ID8 murine OvCa cells to the omentum in vivo and their migration and invasion in 3D-cocultures in vitro. Mechanistic studies using human and murine adipocyte-OvCa genetically manipulated for SPARC expression in 3D co-cultures, revealed that the effect of SPARC suppressing adipocyte-OvCa cell cross-talk mediated by the effect suppressing the activation of cEBP-β, NFκB and AP-1 in OvCa cells as well as in adipocytes with subsequent decrease in chemokines/adipokines as well as fatty acid exchange between OvCa cells and adipocytes. Our data indicates the metastasis suppressor effect of SPARC in POC is mediated in part via inhibiting the key transcription factors involved in adipocytes differentiation and OvCa progression identifying SPARC as a potential inhibitor of OvCa cell omental seeding and dormancy. Citation Format: Dylan P. Matthews, Neveen A. Said. Regulation of omental seeding of ovarian cancer cells by SPARC. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1651. doi:10.1158/1538-7445.AM2013-1651
EFICACIA DE UN SISTEMA DE FILTRO DE PETICIONES DE COLONOSCOPIAS EN UN SISTEMA DE CITACIÓN ABIERTO: DISMINUCION DE LA SOBREINDICACIÓN Y CONTROL DE LA DEMORA
Authors: P Díez Redondo, S Lorenzo Pelayo, P Gil Simón, MT Herranz Bachiller, N Alcaide Suárez, C de La Serna-Higuera, M Pérez-Miranda
Journal: Endoscopy (2011)

Introducción: Mantener la eficiencia de un sistema abierto de petición de colonoscopia puede requerir minimizar la sobreindicación y considerar la diferente naturaleza de las solicitudes.
Abstract P5-10-11: Clinical significance of microRNA expression as a prognostic factor in early N+ breast cancer (BC)
Authors: EM Ciruelos, GA de Velasco, C Castañeda, JL Rodriguez-Peralto, A Gamez, JM Sepúlveda, H Cortés-Funes, DE Castellano, JA Fresno
Journal: Cancer Research (2012)

Abstract Background: microRNAs (miRNAs) are small noncoding RNA molecules that post-transcriptionally regulate gene expression. In the present study, we describe miRNA expression in early node-positive BC and identify a 8-miRNA score that could contribute to prognosis assessment. Methods: First, microarray analysis was performed using RNA samples extracted from primary breast cancer. The expression of miRNAs was analyzed by RT-qPCR using the TaqMan Arrays from Applied Biosystems. After a suitable normalization of the 677 miRNAs analyzed, 123 presented a good correlation between their levels of expression in frozen tissue and paraffin tissue. A supervised analysis was done in order to identify MIR that could predict relapse. Results: 172 patients with node-positive chemotherapy-treated early BC were included in the present study. The median age at diagnosis was (53.7) years, 128 cases (74.4%) had positive estrogen receptor, and 163 patients (94,7%) received adjuvant chemotherapy. After a median follow up of 8,1 years, 71p (41.2%) relapsed. Supervised analyses identified 8 microRNAs (has miR-30e, miR-30a, miR-21, miR-210, miR-93, miR-150, miR-99b, miR-572) associated with higher risk of relapse (5 year PFS 50% vs 90%, HR 3.75, 95% CI 2.27–6.19) and with estimated overall survival (median not reached, HR 4.51, 95% CI 2.36–8.61). Interestingly, miRNAs defined 2 prognostic groups (high and low risk) regardless of type of adjuvant chemotherapy (with or without anthracyclines) and histological subtype (luminal A, B or triple negative). Conclusions: This study suggests that miRNA expression could contribute to assess molecular prognosis of breast cancer and identifies clusters of miRNAs that could improve outcome prediction. A validation study in node-negative and triple negative disease is planned. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-10-11.
Neural-Tube Defects
Authors: Lorenzo D. Botto, Cynthia A. Moore, Muin J. Khoury, J. David Erickson
Journal: New England Journal of Medicine (1999)

Each year spina bifida and anencephaly, the two most common forms of neural-tube defects, occur in 1 in 1000 pregnancies in the United States1 and an estimated 300,000 or more newborns worldwide.2 Although these severe conditions have been recognized since antiquity, never before has progress been so fast and substantive, particularly in the area of prevention. The results of randomized trials indicate that at least half the cases of neural-tube defects could be prevented if women consumed sufficient amounts of the B vitamin folic acid before conception and during early pregnancy.3,4 Elsewhere in this issue of the Journal, Berry . . .
P601Cardio-protective effects of exercise are abolished in pressure-overload following aortic constriction by increased eNOS uncoupling and oxidative stress
Authors: Y Octavia, ED Van Deel, MC De Waard, AL Moens, DJ Duncker
Journal: Cardiovascular Research (2014)

Purpose: Cardio-protective effects of physical exercise training are generally recognized. However, previously we demonstrated that the beneficial effects of exercise critically depend on the underlying cause of cardiac dysfunction and showed that unlike following myocardial infarction (MI), exercise did not improve but rather tended to aggravate cardiac dysfunction and remodeling following mild and severe pressure-overload induced by a trans-aortic constriction (TAC). The mechanism behind the etiology-dependent effects of exercise in cardiac disease remains unclear but we hypothesize that nitric oxide synthases (NOS) dependent regulation of the balance between nitric oxide and superoxide (O2•−) is critically involved.
Abstract 76: Epigenetic silencing of argininosuccinate synthetase renders human bladder cancer cells sensitive to pegylated arginine deiminase
Authors: Michael Allen, Nelofer Syed, Fiona Luong, Kimberley Howarth, Patricia Gorman, Ian Tomlinson, Rebecca Roylance, Yong-Jie Lu, Lemoine Nicholas, Berney Dan, Tim Crook, Peter W. Szlosarek
Journal: Cancer Research (2011)

Abstract Tumors deficient in argininosuccinate synthetase (ASS1), a key enzyme involved in arginine synthesis, are auxtrophic for arginine and sensitive to amino acid deprivation. Based on reports of instability at 9q34 in bladder cancer, the locus of ASS1, we investigated ASS1 status using a variety of molecular and genetic techniques and assessed the impact of arginine deprivation on the viability of bladder cancer cell lines in vitro and in vivo. Initially, we revealed very low mRNA levels and no ASS1 protein in 3 of 7 bladder cancer cell lines (253J, EJ28 and UMUC-3). The ASS1-negative cell lines were all hypermethylated at the ASS1 promoter, compared with the ASS1-positive cell lines, which were hypomethylated. There was no evidence for ASS1 mutations by gene sequencing or loss of heterozygosity by fluorescence in situ hybridization and single nucleotide polymorphism arrays. An analysis of 48 patients with bladder cancer revealed 65% were ASS1-negative by immunohistochemistry, with evidence for ASS1 methylation as the mechanism for ASS1 inactivation. The arginine depleting agent, pegylated arginine deiminase (ADI-PEG20), triggered caspase-dependent and independent apoptosis of 253J and EJ28 cell lines, respectively, whereas ASS1-positive control bladder cell lines were resistant to ADI-PEG20. We have identified downregulation of ribonucleotide reductase M2 (RRM2) as a biomarker of ADI-PEG20 activity and ongoing work is focused on combining ADI-PEG20 with cisplatin-doublet chemotherapy in vivo. In summary, we propose that epigenetic silencing of ASS1 renders bladder cancer sensitive to ADI-PEG20, providing a novel approach for the treatment of a common and therapeutically challenging cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 76. doi:10.1158/1538-7445.AM2011-76
Insulin-Injection-Site Reactions Associated with Type I Latex Allergy
Authors: M.A.B. Roest, S. Shaw, D.I. Orton
Journal: New England Journal of Medicine (2003)

to the editor: We recently reported (April 18 issue) 1 the sustained correction of X-linked severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the g c gene into CD34+ cells in four of five patients with the disease.These results have since been confirmed in four additional patients with typical X-linked severe combined immunodeficiency.Of the first four successfully treated patients, three continue to do well up to 3.6 years after gene therapy, whereas a serious adverse event occurred in the fourth patient.At a routine checkup 30 months after gene therapy, lymphocytosis consisting of a monoclonal population of V g 9/V d 1, g / d T cells of mature phenotype was detected.One proviral integration site was found, located on the short arm of chromosome 11 within the LMO-2 locus, as determined with the use of linearamplification mediated polymerase-chain-reaction analysis. 2This proviral integration within the LMO-2 locus was associated with aberrant expression of the LMO-2 transcript in the monoclonal T-cell population.Aberrant expression of LMO-2 has been reported in acute lymphoblastic leukemia arising from T cells with a / b receptors, usually with the chromosomal translocation t(11;14). 3Tests for replicationcompetent retrovirus were repeatedly negative in our patient's lymphocytes.Between 30 and 34 months after gene therapy, the patient's lymphocyte count rose to 300,000 per cubic millimeter, and hepatosplenomegaly developed.Further investigations showed the presence of a t(6;13) translocation, which had not been detected 30 months after the therapy.Treatment with a chemotherapy regimen based on a high-risk protocol for acute lymphocytic leukemia (a protocol of the Dutch Childhood Leukemia Study Group) was initiated and has resulted, to date, in a dramatic reduction in the abnormal cells.
Abstract 3008: PNA based microarray for cancer &amp; stem cell related miRNAs profiling from low total RNA with on-chip labeling
Authors: Kim Hyunsun, Jae-Jin Choi, Minhye cho, Heekyung Park
Journal: Cancer Research (2010)

Abstract MicroRNAs(miRNAs) are short non-coding RNAs that play a critical role in many important biological processes. MiRNA expression profiling is important to understand the biological mechanisms, develop drugs, and diagnose. However, analyzed method of expression profiling is limited for short base of miRNA. Microarray which is hybridization based technique is the best for detection tool on miRNA characteristic. So, we have developed a PNA-based microarray that is highly sensitive, specific and reproducible to analyze miRNA expression profiles with direct miRNA labeling on chip after hybridization. PNA probes are well known to have stronger binding affinity, specificity to its complementary DNA or RNA strand and stability to biological enzymes. Unlabeled total RNA is hybridized to the PNA-based microarray for 4 hours and then only hybridized miRNA labeling is performed by using enzymatic ligation with pCp-Cy3. Labeling method of only hybridized miRNAs is an important technique for reproducibility and reliable results of microarray. Our data showed very low cross hybridization for miRNAs differing by single nucleotide such as human let7 family and miR-181 family. We used this microarray to determine the profile of microRNAs expressed in the developing cancer cell lines and Tissue. Array results have been validated by subsequent confirmation of miRNA expression using TaqMan qRT-PCR analysis. The results from the TaqMan qRT-PCR and PNA based microarray are shown that the range of correlation were 0.904-0.989. PNA-based microarray platform can detect small amounts of individual miRNAs from &amp;lt;400ng of total RNA with above 99% correlation between independent replicates in 6hrs. Therefore, PANArrayTM miRNA can be a powerful tool to analyze miRNA expression profiling in cancer diagnosis and prognosis for high throughput screening with high accuracy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3008.